Genomtec (GMT) Q4 2025 earnings summary

Executive summary

• 2025 marked a year of structural reorganization and intensified commercialization efforts, including the creation of two special purpose vehicles for key projects, Genomtec ID and OncoSNAAT, enhancing transactional flexibility and strategic focus.

• Major patent milestones were achieved, expanding protection to 20 patents and over 30 applications globally, with new filings in oncology and molecular diagnostics.

• Strategic partnerships were established, notably with Lynx Financial in Shanghai, opening access to Asian markets.

• Significant cost reductions in microfluidic card production (over 70%) and reagents (up to 80%) were realized, boosting competitiveness.

• Financial stability was supported by a PLN 11 million share issue and grants, with further capital raises planned for 2026.

Financial highlights

• Consolidated revenue from sales reached PLN 21k in 2025, up from PLN 1k in 2024.

• Grant income rose to PLN 4.5m, a 94% increase year-over-year.

• Net loss narrowed to PLN -10.4m from PLN -11.2m year-over-year.

• Cash and equivalents at year-end were PLN 4.7m, down from PLN 6.7m in 2024.

• Equity increased to PLN 9.2m from PLN 7.6m year-over-year.

Outlook and guidance

• Strategic focus remains on successful commercialization of Genomtec ID (sale or licensing) and securing a strategic partner for OncoSNAAT.

• Ongoing AI-driven diagnostic test design project, supported by a PLN 7m grant, aims to accelerate product development.

• Planned capital increases in 2026 (up to 2 million new shares) to fund M&A and R&D activities.

• The oncology project will advance to prototype phase, leveraging a PLN 21m grant.